Skip to content

The role of NGF/TrKA signaling pathway and downstream signaling molecule TRPV1 in pathological pain of advanced knee osteoarthritis and the intervention of traditional Chinese medicine external treatment method

The role of NGF/TrKA signaling pathway in advanced knee osteoarthritis pain and the basic and clinical application of ''warming the meridian and promoting blood circulation'' external therapy intervention

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100048995
Enrollment
Unknown
Registered
2021-07-19
Start date
2021-07-19
Completion date
Unknown
Last updated
2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis

Interventions

KOA group:Total knee arthroplasty
Non-KOA group:Arthroscopic knee surgery

Sponsors

Kunshan Third People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. KOA group (1) For patients with knee osteoarthritis, the KOA diagnostic criteria in the 2007 edition of "Guidelines for the Diagnosis and Treatment of Osteoarthritis": 1) Repeated knee pain within 1 month; 2) X-ray films showed joint space narrowing, subchondral bone sclerosis and/or cystic degeneration, and osteophyte formation at the joint edge; 3) Clear joint fluid, WBC= 40 years; 5) Morning stiffness = 4). 2. Inclusion criteria for non-KOA group: (1) Aged >=40 years; (2) No previous history of knee fracture; (3) Arthroscopic surgery is required for discoid meniscus, meniscus injury, popliteal cyst, etc.; (4) Outerbridge arthroscopic cartilage injury grade 1 month.

Exclusion criteria

Exclusion criteria: 1. Those with skin ulceration of the knee joint, or those with a history of surgery or intra-articular hormone injection; 2. Immune and immune-related arthritis, such as gouty arthritis, rheumatoid arthritis, reactive arthritis, psoriatic arthritis, etc.; 3. Patients with renal insufficiency and a history of malignant tumors; 4. Infectious arthritis, tuberculosis.

Design outcomes

Primary

MeasureTime frame
Visual analogue scale;Nerve growth factor;

Secondary

MeasureTime frame
Pain sensitivity threshold;Skin temperature;Tyrosine kinase A;Transient receptor potential vanillic acid subtype 1;

Countries

China

Contacts

Public ContactLi Mingchao

Kunshan Third People's Hospital

114801575@qq.com+86 18068081787

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026